Literature DB >> 11084057

Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.

C A Sponseller1, B R Bacon, A M Di Bisceglie.   

Abstract

Lamivudine is effective in inhibiting hepatitis B virus (HBV) replication, and its clinical use in patients with chronic hepatitis B is associated with improvements in serum aminotransferase levels and liver histopathologic characteristics. Few data are available on its use in patients with advanced liver disease. We report on the outcomes of 5 patients with hepatic decompensation caused by chronic hepatitis B treated long term with lamivudine. All patients were adult white men seropositive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) before therapy. All 5 patients had biopsy-proven cirrhosis with clinical and biochemical evidence of hepatic decompensation. Two patients had Child's class C cirrhosis; 2 patients, class B; and 1 patient, class A (although this patient had persistent portasystemic encephalopathy and developed variceal bleeding). HBV DNA became undetectable in all patients and remained so throughout the study. Both patients with Child's class C and 1 patient with class B cirrhosis had significant clinical improvement. Child-Pugh scores improved from 12 to 7 and 11 to 7 in the 2 patients with Child's class C cirrhosis, and the patient with class B cirrhosis had complete resolution of troublesome encephalopathy. Serum aminotransferase, albumin, and total bilirubin levels improved significantly in 3 of 5 patients. One patient with Child's class B cirrhosis underwent orthotopic liver transplantation at week 13 after dramatic increases in liver tests and clinical worsening. The patient subsequently cleared HBeAg and HBsAg from serum posttransplantation. In conclusion, prolonged therapy with lamivudine resulted in improved serum biochemical values and loss of HBV DNA in patients with decompensated cirrhosis. Clinical improvements, reflected in Child-Pugh classification and functional status, may also occur, particularly among those with Child's class C disease initially.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084057     DOI: 10.1053/jlts.2000.18501

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Treatment of chronic hepatitis.

Authors:  P J Gow; D Mutimer
Journal:  BMJ       Date:  2001-11-17

2.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 3.  Treatment of hepatitis B and C following liver transplantation.

Authors:  Craig A Sponseller; Sanjay Ramrakhiani
Journal:  Curr Gastroenterol Rep       Date:  2002-02

4.  Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report.

Authors:  Yuka Suzuki; Hiroshi Yotsuyanagi; Chiaki Okuse; Yoshihiko Nagase; Hideaki Takahashi; Kyoji Moriya; Michihiro Suzuki; Kazuhiko Koike; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

5.  Management of chronic hepatitis B: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

Review 6.  Prevention and Management of Chronic Hepatitis B.

Authors:  Mamatha Bhat; Peter Ghali; Marc Deschenes; Philip Wong
Journal:  Int J Prev Med       Date:  2014-12

7.  Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients.

Authors:  Makoto Nakamuta; Kazuhiro Kotoh; Munechika Enjoji; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Norihiro Furusyo; Hideyuki Nomura; Hironori Sakai; Kazuhiro Takahashi; Koichi Azuma; Shinji Shimoda; Yuichi Tanabe; Jun Hayashi
Journal:  Comp Hepatol       Date:  2007-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.